Literature DB >> 8215628

Treatment of Paget's disease of bone with single dose intravenous pamidronate.

R A Watts1, S J Skingle, M M Bhambhani, G Pountain, A J Crisp.   

Abstract

OBJECTIVES: To assess the efficacy of a single intravenous infusion of pamidronate in Paget's disease of bone.
METHODS: Fourteen patients with active Paget's disease (raised serum alkaline phosphatase, bone pain or neurological involvement) were treated with a single intravenous infusion of 105 mg pamidronate. Patients were assessed for biochemical and clinical improvement for up to two years following treatment. A further infusion was given following symptomatic relapse (pain at a known site of pagetic involvement).
RESULTS: Serum alkaline phosphatase fell following treatment, with a nadir 5.9 months after treatment. Bone pain was improved in nine of 12 patients after six months. Retreatment of four patients resulted in a similar response.
CONCLUSION: Single dose intravenous pamidronate (105 mg) is a convenient and effective treatment for Paget's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8215628      PMCID: PMC1005123          DOI: 10.1136/ard.52.8.616

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

1.  Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses.

Authors:  A J Fenton; D H Gutteridge; G N Kent; R I Price; R W Retallack; C I Bhagat; G K Worth; R I Thompson; I G Watson; C Barry-Walsh
Journal:  Clin Endocrinol (Oxf)       Date:  1991-03       Impact factor: 3.478

2.  Absorption of oral diphosphonate in normal subjects.

Authors:  I Fogelman; L Smith; R Mazess; M A Wilson; J A Bevan
Journal:  Clin Endocrinol (Oxf)       Date:  1986-01       Impact factor: 3.478

3.  Reduction of skeletal blood flow in Paget's disease with disodium etidronate therapy.

Authors:  K R Walton; J R Green; J Reeve; R Wootton
Journal:  Bone       Date:  1985       Impact factor: 4.398

4.  Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).

Authors:  H I Harinck; S E Papapoulos; H J Blanksma; A J Moolenaar; P Vermeij; O L Bijvoet
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-21

5.  A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.

Authors:  D Thiébaud; P Jaeger; C Gobelet; A F Jacquet; P Burckhardt
Journal:  Am J Med       Date:  1988-08       Impact factor: 4.965

6.  Clinical experience with pamidronate in the treatment of Paget's disease of bone.

Authors:  S J Gallacher; B F Boyce; U Patel; A Jenkins; S H Ralston; I T Boyle
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

7.  Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.

Authors:  J A Cantrill; H M Buckler; D C Anderson
Journal:  Ann Rheum Dis       Date:  1986-12       Impact factor: 19.103

8.  Treatment of Paget's disease by weekly infusions of 3-aminohydroxypropylidene-1,1-bisphosphonate (APD).

Authors:  P J Ryan; M Sherry; T Gibson; I Fogelman
Journal:  Br J Rheumatol       Date:  1992-02

9.  Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate); a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1,1-bisphosphonate).

Authors:  T R Fraser; H K Ibbertson; I M Holdaway; M Rutland; A King; G Dodd; D J Wattie
Journal:  Aust N Z J Med       Date:  1984-12

10.  Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease.

Authors:  E Vega; D Gonzalez; G Ghiringhelli; C Mautalen
Journal:  J Bone Miner Res       Date:  1987-08       Impact factor: 6.741

View more
  4 in total

1.  Disodium pamidronate has beneficial effect in Paget's disease of bone.

Authors:  K Chakravarty; P Merry; D G Scott
Journal:  BMJ       Date:  1996-06-08

Review 2.  Pathogenesis and clinical aspects of pain in patients with osteoporosis.

Authors:  Rocco Domenico Mediati; Renato Vellucci; Lucia Dodaro
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

Review 3.  Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.

Authors:  A J Coukell; A Markham
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

4.  Acute effects of bisphosphonates on new and traditional markers of bone resorption.

Authors:  M Pedrazzoni; F S Alfano; C Gatti; M Fantuzzi; G Girasole; C Campanini; G Basini; M Passeri
Journal:  Calcif Tissue Int       Date:  1995-07       Impact factor: 4.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.